吲哚美辛(Indomethacin) - 药物靶点：COXs_在研适应症：动脉导管未闭，炎症，肌痛_专利_临床

概要

基本信息

简介吲哚美辛是一种小分子，属于非甾体类抗炎药 (NSAID)，通过抑制 COX 酶，可阻止炎症和疼痛。该药物可用于治疗多种疾病，包括动脉导管、关节炎、网球肘、急性臂神经炎、痛风性关节炎、强直性脊柱炎、滑囊炎、肌腱病、骨关节炎、类风湿性关节炎、肿胀、疼痛、肘部肌腱病、炎症和肌肉骨骼疼痛。由 iROKO Partners Ltd. 开发，于 1965 年 6 月获得批准。

药物类型

小分子化药

别名

IM-P、Indaflex、Indometacin

+ [32]

靶点

COXs

作用方式

抑制剂

作用机制

COX抑制剂(环氧化酶抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Teikoku Seiyaku Co. Ltd.

University of California San Diego

+ [8]

非在研机构

Novartis AG

Rising Pharmaceuticals, Inc.

北京世纪利伟医药科技发展有限公司

+ [7]

权益机构

Zyla Life Sciences LLC

Assertio Holdings, Inc.

Cosette Pharmaceuticals, Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (1965-06-10),

强直性脊柱炎滑囊炎骨关节炎+ [4]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C19H16ClNO4

InChIKeyCGIGDMFJXJATDK-UHFFFAOYSA-N

CAS号53-86-1

关联

234

项与吲哚美辛相关的临床试验

NCT07218653

/ Not yet recruiting早期临床1期IIT

Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome

This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Healthy Controls versus participants with MetSyn.

开始日期2026-11-01

申办/合作机构

University of Wisconsin-Madison

[+1]

NCT07792668

/ Not yet recruiting临床4期IIT

Comparison of No Premedication, Rectal Indomethacin Suppository, and Paracervical Block for Pain Reduction During Hysterosalpingography: A Prospective Randomized Three-Arm Controlled Trial

Hysterosalpingography (HSG) is commonly performed during infertility evaluation and may cause pain during cervical manipulation, uterine distension, and contrast-medium injection. This prospective, randomized, three-arm controlled trial will compare three pain-control approaches during HSG: no analgesic premedication, rectal indomethacin administered before the procedure, and paracervical block with lidocaine. Eligible women scheduled for diagnostic HSG will be randomized in a 1:1:1 ratio. The primary outcome will be participant-reported pain during contrast-medium injection measured using an 11-point Numeric Rating Scale (NRS) ranging from 0 to 10. Secondary outcomes will include pain during other procedural stages, immediate and 30-minute post-procedural pain, preprocedural anxiety, anticipated pain, rescue analgesic requirement, participant satisfaction, and adverse events.

开始日期2026-11-01

申办/合作机构

Balikesir Üniversitesi

NCT07826026

/ Not yet recruitingN/AIIT

Rectal Indomethacin Alone Versus Rectal Indomethacin Plus Post-procedural Papillary Ice Water Irrigation for Prevention of Post-ERCP Pancreatitis (N-ICE Trial): A Randomized, Patient- and Assessor-Blinded, Superiority Multicenter Trial

Post-endoscopic retrograde cholangiopancreatography pancreatitis (post-ERCP pancreatitis, or PEP) is inflammation of the pancreas that can occur after an ERCP procedure. Rectal indomethacin is commonly given around the time of ERCP to help reduce this risk, but pancreatitis can still occur despite this treatment.
The purpose of this randomized clinical trial is to determine whether adding ice water irrigation of the papilla at the end of ERCP further reduces the risk of post-ERCP pancreatitis compared with rectal indomethacin alone. The papilla is the small opening in the intestine where the bile duct and pancreatic duct drain.
Participants will be randomly assigned to one of two groups. Both groups will receive rectal indomethacin 100 mg. In the intervention group, the doctor will also irrigate the papilla with a total of 250 mL of ice water immediately after the ERCP. Participants and the study team members who assess study outcomes will not know which treatment group the participant was assigned to. Participants will be assessed after ERCP and followed for up to 30 days for pancreatitis and other complications.

开始日期2026-10-01

申办/合作机构

Unity Health Toronto

100 项与吲哚美辛相关的临床结果

登录后查看更多信息

100 项与吲哚美辛相关的转化医学

登录后查看更多信息

100 项与吲哚美辛相关的专利（医药）

登录后查看更多信息

42,726

项与吲哚美辛相关的文献（医药）

2027-01-01·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Impact of phosphate buffer strength and unbuffered water on ionizable drug powder dissolution

Article

作者: Polli, James E ; Patel, Roshni P

We are unaware of prior reports of the dependence of drug powder dissolution on buffer strength. The objective was to assess the effect of 5, 10, 50, and 100 mM sodium phosphate concentration on in vitro particle dissolution of ionizable drugs. Three weakly acidic drugs (naproxen, piroxicam, and phenytoin) and one weakly basic drug (dipyridamole) were studied at different pH conditions. Dissolution was conducted using USP Apparatus II with a mini-paddle at 37 °C in 100 mL media. Overall, the effect on dissolution profile was modest, with the largest effect generally being between 5 mM phosphate and zero phosphate (i.e., unbuffered water). Hence, a secondary objective was to predict the dissolution of the four ionizable drugs into unbuffered water, as well as for ibuprofen, ketoprofen, indomethacin, haloperidol, and meloxicam. Predictions anticipated slower ionizable drug dissolution into unbuffered water. Overall, dissolution predictions into buffer were better using the transient pH film model that accounts for the changing solid-liquid interfacial pH during dissolution, than for the conventional z-factor film model.

2026-12-31·Journal of Maternal-Fetal & Neonatal Medicine

Antenatal tocolytic exposure and postnatal patent ductus arteriosus outcomes in preterm infants born at ≤32 weeks: a retrospective cohort study

Article

作者: Tutak, Ercan ; Doğan, Eser ; Özdemir, Sevim Özge ; Cındık, Nimet ; Ayhan, Yunus Emre ; Öztürk, Gözde

OBJECTIVES:

The impact of antenatal tocolytic therapy on postnatal patent ductus arteriosus (PDA) outcomes in preterm infants remains unclear. Previous studies have rarely evaluated clinically significant treatment-requiring PDA and treatment resistance as distinct but related outcomes. This study aimed to evaluate the association between antenatal tocolytic exposure and postnatal PDA outcomes in infants born at ≤32 weeks of gestation.

METHODS:

In this single-center retrospective cohort study, preterm infants (≤32 weeks) admitted to a tertiary neonatal intensive care unit between January 2018 and August 2025 and undergoing echocardiographic evaluation were included. Infants were classified as exposed or unexposed to antenatal tocolytics and further categorized as receiving indomethacin-containing or indomethacin-free regimens. Primary outcomes were clinically significant treatment-requiring PDA supported by echocardiographic criteria and pharmacological treatment resistance. Multivariable logistic regression and propensity score-based inverse probability of treatment weighting (IPTW) analyses were performed.

RESULTS:

Among 236 infants, 53 (22.5%) were exposed to antenatal tocolytics. Clinically significant treatment-requiring PDA was identified in 87 infants (36.9%). Tocolytic exposure was independently associated with a lower likelihood of treatment-requiring PDA in the original adjusted model (aOR 0.377, 95% CI 0.17-0.85; p = 0.018) and in an expanded model including multiple gestation (aOR 0.368, 95% CI 0.15-0.87; p = 0.023). In contrast, among infants who developed treatment-requiring PDA, exposure was associated with treatment resistance (original model: aOR 21.802, 95% CI 2.72-175.02; p = 0.004; IPTW analysis: OR 8.794, 95% CI 1.46-52.96; p = 0.018). Among tocolytic-exposed infants, treatment-requiring PDA was more frequent after indomethacin-containing than indomethacin-free regimens (41.7% vs 13.8%, p = 0.022).

CONCLUSIONS:

Antenatal tocolytic exposure was associated with a lower overall likelihood of clinically significant treatment-requiring PDA, whereas treatment resistance among infants who developed treatment-requiring PDA was more frequent, particularly after indomethacin-containing regimens. These observational findings should be interpreted as hypothesis-generating because of potential residual confounding, practice-dependent outcome assessment, and small subgroup sizes.

2026-12-31·Journal of Maternal-Fetal & Neonatal Medicine

Long-term indomethacin therapy and cervical stabilization in dichorionic twin pregnancies

Article

作者: Goetzinger, Katherine ; Turan, Sifa ; Bucak, Mevlut ; Harman, Christopher ; Seif, Karl ; Turan, Ozhan

OBJECTIVE:

To evaluate the effect of long-term indomethacin therapy (LIT) in stabilizing cervical length in dichorionic-diamniotic (DCDA) twin pregnancies with a short cervix.

METHODS:

This retrospective cohort study included 54 dichorionic-diamniotic twin pregnancies with a short cervix (≤25 mm), managed with LIT between 18 and 26 weeks of gestation age (GA) at a single quaternary medical center from 2014 to 2024. LIT was initiated with a 100 mg oral loading dose, followed by 50 mg every 6 h for 48 h, and continued at 25 mg every 6 h until 32 weeks or delivery. Weekly monitoring included transvaginal ultrasound, amniotic fluid assessment, and fetal Doppler studies. The expected cervical length (E_LCL) was modeled by applying an assumed physiologic cervical shortening rate of 0.9 mm per week to the observed first cervical length (O_FCL) in twin pregnancies without intervention. E_CL = O_FCL - [(GA at O_LCL - GA at O_FCL (weeks)) × 0.9 (mm/week)]. Cervical stabilization was defined as the observed last cervical length (O_LCL) exceeding the expected last cervical length (E_LCL) at the last examination. The primary outcome was cervical stabilization, while the secondary outcome was gestational age at delivery.

RESULTS:

LIT was successful in stabilizing the cervix in 81.5% (n = 44/54) of cases. The mean GA at LIT onset was 22.9 ± 1.9 weeks, with a median O_FCL of 14.5 mm (IQR: 10.0-18.0). The mean duration of LIT was 48 days (IQR: 25-61). Final O_LCL was significantly longer than E_LCL (15.9 ± 6.1 mm vs. 9.3 ± 5.9 mm, p < .001). Median gestational age at delivery was higher in stabilized vs. non-stabilized patients (34.6 weeks [IQR: 31.7-36.6] vs. 30.8 weeks [IQR: 26.1-32.3], p = .004). No difference was observed in initial cervical length between groups (p = .282). LIT was discontinued in 11.2% due to ductus arteriosus constriction or oligohydramnios; no adverse neonatal outcomes were reported.

CONCLUSION:

These findings suggest an association between LIT and cervical stabilization in DCDA twin pregnancies with a short cervix; this exploratory, hypothesis-generating analysis warrants confirmation in prospective studies.

262

项与吲哚美辛相关的新闻（医药）

2026-11-06

·FierceBiotech

AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera

AbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease (IBD) candidate. In exchange for the worldwide rights to develop the oral EP4 receptor agonist, dubbed NXE0033744, in IBD, AbbVie is also liable to pay up to $1.37 billion in development and commercial milestones, as well as tiered royalties should the candidate make it to market. AbbVie is already a major player in the IBD space, courtesy of the blockbuster trio of Humira, Skyrizi and Rinvoq. Nxera has pitched NXE0033744—which was developed with the biopharma’s NxWave drug discovery platform— as serving the “significant unmet need of people with IBD that do not achieve satisfactory disease control.” The theory is that by selectively activating EP4 receptors in the gastrointestinal tract, the drug can produce anti-inflammatory effects and mucosal healing, according to Nxera’s Nov. 4 release. The biotech has taken NXE0033744 through a phase 1 trial that demonstrated “a gut-restricted profile and target engagement through a reduction in indomethacin-induced intestinal permeability,” it explained in this morning’s release. Both companies are not the only ones that have shown an interest in E2 receptor 4 (EP4) as a tempting target. Ono Pharmaceutical’s ONO-4578 , which is an antagonist of EP4 rather than an agonist, has already caught the attention of Bristol Myers Squibb for its potential to treat gastric cancer. Nxera, which was previously called Sosei, announced late last year that it was pulling back from the IBD program for NXE0033744 as part of a restructuring of its pipeline and workforce. At the time, Nxera CEO Christopher Cargill said the program has gone “extremely well,” but argued that the level of competition in a setting he described as a “very, very complex and expensive area to be developing an asset” had driven the company to rethink its plans. Announcing AbbVie’s decision yesterday to buy NXE0033744, Cargill said the Big Pharma was the “ideal partner to advance the program globally and determine whether this biology can translate into measurable, life-changing outcomes for people with IBD.” Cargill put the licensing agreement in the context of the two companies’ long-running relationship, which includes an inflammatory and autoimmune-focused pact in 2020, followed by a 2022 deal to work on drugs for neurological diseases. “AbbVie is already an important partner to Nxera through our ongoing neuroscience discovery collaboration, and this agreement is a strong vote of confidence in NxWave’s ability to consistently deliver,” Cargill added. “The upfront payment, together with potential near-term milestone payments, will further strengthen our financial position while enabling Nxera to share in the future success of NXE0033744 and the value it may create.” Where Big Pharma is placing its bets is one of the hot topics being discussed at Fierce Biotech's high-impact event in London next month. Find out more information and register by clicking on the banner below: The content above comes from the network. if any infringement, please contact us to modify.

引进/卖出

2026-11-04

·药明康德

失眠症药物获FDA突破性疗法认定，艾伯维达成最高14.7亿美元授权合作，引进潜在“first-in-class”口服EP4激动剂……｜产业新闻

失眠症药物获FDA突破性疗法认定，2期研究显示儿童患者睡眠时间延长 Idorsia宣布，美国FDA授予双重食欲素受体拮抗剂（DORA）daridorexant突破性疗法认定，用于治疗10岁至不满18岁儿童及青少年的失眠障碍。这一认定基于该药在大型2期临床研究中的积极结果，也体现了儿童及青少年失眠症领域尚未满足的医疗需求。目前，美国FDA尚未批准任何专门用于治疗儿童及青少年失眠障碍的药物。 Daridorexant是一款由Idorsia开发的口服DORA药物，已以Quviviq为商品名获批用于成人失眠障碍。该药通过阻断食欲素受体，降低大脑维持清醒状态的信号活性，帮助患者入睡并维持睡眠。与广泛抑制中枢神经系统活性的传统镇静催眠药物不同，daridorexant主要针对调控觉醒状态的食欲素信号系统发挥作用。儿童及青少年失眠障碍可能表现为入睡困难、睡眠维持困难及日间功能受损，并影响注意力、学习能力、情绪调节和生活质量。对于患有自闭症谱系障碍或注意缺陷多动障碍（ADHD）等神经发育障碍的儿童，睡眠问题可能造成更为显著的影响。此次突破性疗法认定主要基于一项多中心、随机、双盲、安慰剂对照2期剂量探索研究。研究共纳入165例年龄为10岁至不满18岁的失眠障碍患者，随机接受daridorexant 10 mg、25 mg、50 mg或安慰剂治疗，持续两周。研究主要终点为首次给药后第1天，通过多导睡眠监测（PSG）测得的总睡眠时间（TST）较基线的变化。结果显示，daridorexant在整体儿童及青少年患者中呈现出具有统计学显著性的剂量依赖性睡眠时间改善（P=0.0185）。其中，接受单次50 mg剂量治疗后，患者的总睡眠时间较基线增加50分钟，而在患有神经发育障碍的儿童及青少年中，总睡眠时间增加64分钟。研究还在多项客观及主观睡眠指标中观察到剂量依赖性的改善，并发现晨起困倦程度呈数值下降趋势。安全性方面，daridorexant在儿童及青少年患者中总体耐受性良好，即使在50 mg剂量下，其安全性特征也与安慰剂相近。 Idorsia表示，正在根据全球监管机构的反馈完善儿童及青少年失眠障碍3期临床开发方案，预计于2027年下半年启动相关研究。艾伯维达成最高14.7亿美元授权合作，引进潜在“first-in-class”口服EP4激动剂艾伯维（AbbVie）与Nxera Pharma宣布达成全球独家许可协议，获得Nxera旗下EP4受体激动剂项目（包括NXE0033744）针对炎症性肠病的全球独家开发及商业化权利。根据协议，Nxera将获得1亿美元首付款，并有资格获得最高13.7亿美元的开发及商业化里程碑付款。 NXE0033744是一款潜在“first-in-class”口服小分子EP4受体激动剂，利用Nxera专有的NxWave药物发现平台开发。该药旨在选择性激活胃肠道局部的EP4受体，发挥抗炎作用，同时促进肠道上皮屏障功能维持和黏膜修复，为炎症性肠病提供不同于现有疗法的潜在治疗机制。目前，NXE0033744已完成首次人体1期临床研究，包括单次及多次剂量递增研究、溃疡性结肠炎患者队列，以及吲哚美辛（indomethacin）诱导肠道通透性变化的试验队列。研究结果支持该药主要在胃肠道局部发挥作用的特征，并减轻吲哚美辛诱导的肠道通透性增加。研究未报告值得特别关注的不良事件。不过，该药能否在炎症性肠病患者中带来持续的临床缓解或黏膜愈合，仍需后续临床研究验证。勃林格殷格翰达成肿瘤药物授权合作，潜在里程碑付款达70亿美元勃林格殷格翰（Boehringer Ingelheim）与中国生物制药（SBP Group）宣布达成一项多项目选择权及授权许可协议，共同开发基于抗体偶联药物（ADC）和T细胞衔接器（TCE）技术的新型癌症疗法。根据协议，中国生物制药将获得合计3.58亿美元的首付款及近期付款，并有资格获得最高70亿美元的潜在里程碑付款。 ADC通过抗体识别肿瘤细胞表面的特定靶点，将具有细胞毒性的药物递送至肿瘤组织。T细胞衔接器则通过同时结合肿瘤相关抗原和T细胞表面靶点，促进T细胞识别并攻击肿瘤细胞。两类技术分别利用靶向药物递送和免疫细胞募集机制，是当前抗肿瘤药物研发的重要方向。此次合作涵盖六个临床前生物制品项目，其中五个来自中国生物制药旗下的礼新医药（LaNova Medicines），另一个来自旗下的北京泰德制药（Beijing Tide）。双方尚未披露具体候选药物、靶点及临床前研究数据。根据协议，中国生物制药将负责相关项目的早期开发，直至完成全球1期临床试验。达到约定的临床开发里程碑后，勃林格殷格翰可行使选择权，获得相应项目的独家开发、生产及商业化权利。此次协议是双方在肿瘤领域的第二次合作，有望进一步扩充勃林格殷格翰在ADC和T细胞衔接器领域的研发管线。参考资料： [1] Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies. Retrieved November 4, 2026, from https://www.boehringer-ingelheim.com/human-health/boehringer-announces-new-oncology-partnership-sbp-group [2] Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease. Retrieved November 4, 2026, from https://www.globenewswire.com/news-release/2026/11/04/3395033/0/en/nxera-pharma-enters-into-global-license-agreement-with-abbvie-for-nxe0033744-a-novel-ep4-receptor-agonist-for-inflammatory-bowel-disease.html [3] Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder. Retrieved November 4, 2026, from https://www.globenewswire.com/news-release/2026/11/04/3395004/0/en/breakthrough-therapy-designation-granted-by-the-fda-for-daridorexant-in-pediatric-insomnia-disorder.html 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新……

临床2期突破性疗法临床3期引进/卖出

2026-11-04

·BioSpace

Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease

Nxera to receive US$100 million upfront and be eligible for up to US$1.37 billion in development and commercial milestone payments, plus tiered royalties. NXE0033744, an investigational oral EP4 receptor agonist discovered using Nxera’s NxWave™ drug discovery platform, is a potential first-in-class candidate for inflammatory bowel disease. Tokyo, Japan and Cambridge, UK, 4 November 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”; TSE: 4565) today announces that its subsidiary, Nxera Pharma UK Ltd, has entered into an exclusive global license agreement (the “Agreement”) with AbbVie Inc. (“AbbVie”) for Nxera’s EP4 agonist program including NXE0033744, a novel small molecule EP4 receptor agonist discovered by Nxera. Under the Agreement, AbbVie will receive exclusive rights to develop and commercialize NXE0033744 worldwide in inflammatory bowel disease (IBD). Under the terms of the Agreement, Nxera will receive an upfront payment of US$100 million. Nxera is also eligible to receive up to an additional US$1.37 billion in development and commercial milestone payments, plus tiered royalties on net sales. This transaction is subject to customary antitrust clearances including the Hart-Scott-Rodino Antitrust Improvements Act. The $100 million USD upfront payment will represent a material positive revenue impact to Nxera, and is expected to be recognized as revenue in the fourth quarter of the financial year ended December 31, 2026, subject to agreement with the Group's auditors. NXE0033744 is an investigational oral EP4 receptor agonist for the treatment of inflammatory bowel disease discovered using Nxera’s proprietary NxWave™ drug discovery platform. NXE0033744 aims to address the significant unmet need of people with IBD that do not achieve satisfactory disease control. It is designed to selectively activate EP4 receptors locally in the gastrointestinal tract to induce anti-inflammatory effects and to promote epithelial barrier homeostasis and mucosal healing, potentially offering a differentiated mechanism of action from existing treatments. A Phase 1 study has been successfully completed, generating data supporting a gut-selective pro target engagement. Christopher Cargill, President and CEO of Nxera Pharma, commented : “This agreement with AbbVie marks a milestone in the continued development of NXE0033744 and reflects the potential of our NxWave™ platform to generate differentiated medicines for significant unmet needs. NXE0033744 is built on a novel biological approach, designed to activate EP4 locally in the gut to support epithelial barrier homeostasis and mucosal healing, potentially offering a differentiated mechanism of action from existing treatments. AbbVie is already an important partner to Nxera through our ongoing neuroscience discovery collaboration, and this agreement is a strong vote of confidence in NxWave’s ability to consistently deliver. With its deep expertise and proven track record in immunological diseases, and global clinical development, we believe AbbVie is the ideal partner to advance the program globally and determine whether this biology can translate into measurable, life-changing outcomes for people with IBD. The upfront payment, together with potential near-term milestone payments, will further strengthen our financial position while enabling Nxera to share in the future success of NXE0033744 and the value it may create.” –END– About NXE0033744 NXE0033744 is an investigational first-in-class, oral, small-molecule, GI-targeted EP4 receptor agonist in development for inflammatory bowel disease. It was designed using NxWave™ to act locally in the gastrointestinal tract while minimizing systemic exposure. The completed first-in-human Phase 1 program comprised single- and multiple-ascending-dose studies, a cohort of patients with ulcerative colitis and an indomethacin challenge cohort. Results supported a gut-restricted pro demonstrated target engagement through a reduction in indomethacin-induced intestinal permeability. No adverse events of concern were reported. About Inflammatory Bowel Disease Inflammatory bowel disease is a group of chronic, relapsing inflammatory conditions of the gastrointestinal tract, principally ulcerative colitis and Crohn’s disease. Despite advances in treatment, many patients do not achieve or maintain adequate and durable remission or mucosal healing, underscoring the need for therapies with novel mechanisms of action that can improve long-term disease control. About Nxera Pharma Nxera Pharma is a technology-powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies, powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor Relations Shinya Tsuzuki, VP, Head of Investor Relations +81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life MEDiSTRAVA (for International Media) Mark Swallow, Frazer Hall, Erica Hollingsworth +44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

临床1期引进/卖出

100 项与吲哚美辛相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00141	吲哚美辛	C01EB03 S01BC01 M01AB01	DB00328

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性疼痛	美国	Genus Lifesciences, Inc.	2014-02-24
动脉导管未闭	美国	Fresenius Kabi USA LLC	2010-03-17
炎症	日本	Hisamitsu Pharmaceutical Co., Inc.	1989-10-06
肌痛	日本	Teikoku Seiyaku Co. Ltd.	1989-10-06
网球肘	日本	Teikoku Seiyaku Co. Ltd.	1989-10-06
痛风性关节炎	美国	Rising Pharmaceuticals, Inc.	1984-04-20
肩周炎	日本	Kowa Co., Ltd.	1980-03-18
腱鞘炎	日本	Kowa Co., Ltd.	1980-03-18
肿胀	日本	Kowa Co., Ltd.	1980-03-18
疼痛	日本	Kowa Co., Ltd.	1980-03-18
强直性脊柱炎	美国	Zyla Life Sciences US LLC	1965-06-10
滑囊炎	美国	Zyla Life Sciences US LLC	1965-06-10
骨关节炎	美国	Zyla Life Sciences US LLC	1965-06-10
原发性痛风	美国	Zyla Life Sciences US LLC	1965-06-10
类风湿关节炎	美国	Zyla Life Sciences US LLC	1965-06-10
肩痛	美国	Zyla Life Sciences US LLC	1965-06-10
肌腱病	美国	Zyla Life Sciences US LLC	1965-06-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腰痛	临床3期	中国	北京世纪利伟医药科技发展有限公司	2013-10-10
腰痛	临床3期	中国	Teikoku Seiyaku Co. Ltd.	2013-10-10
软组织损伤	临床3期	中国	Teikoku Seiyaku Co. Ltd.	2013-10-10
软组织损伤	临床3期	中国	北京世纪利伟医药科技发展有限公司	2013-10-10
软组织疼痛	临床3期	中国	Teikoku Seiyaku Co. Ltd.	2013-10-10
软组织疼痛	临床3期	中国	北京世纪利伟医药科技发展有限公司	2013-10-10
急性偏头痛	临床3期	美国	Novartis AG	2013-10-01
膝关节炎	临床3期	中国	Teikoku Seiyaku Co. Ltd.	2013-09-27
膝关节炎	临床3期	中国	北京世纪利伟医药科技发展有限公司	2013-09-27
术后疼痛	临床3期	美国	Iroko Pharmaceuticals LLC	2012-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06253702 (CTgov)	临床4期	脑血管疾病	22	Orilissa+estradiol (Female Participants Placebo First)	繭夢憲餘獵壓艱鬱廠膚(廠網範襯鬱構網憲廠鹹) = 觸鹹廠顧齋範積夢顧淵憲獵壓觸鹹範淵衊鑰鬱 (鹽淵繭窪艱衊觸鬱繭顧, 9.35) 更多	-	2026-09-24
				Orilissa+estradiol (Female Participants Indo First)	繭夢憲餘獵壓艱鬱廠膚(廠網範襯鬱構網憲廠鹹) = 願衊選構獵醖鏇糧範簾憲獵壓觸鹹範淵衊鑰鬱 (鹽淵繭窪艱衊觸鬱繭顧, 15.88) 更多
NCT05664074 (CTgov)	临床4期	ERCP术后急性胰腺炎	192	Rectal indomethacin (Rectal Indomethacin)	窪網鑰簾窪觸糧艱顧鏇 = 糧壓鏇範簾顧醖網簾膚鬱獵壓築壓憲艱鹹製願 (範壓觸壓夢範淵淵鬱觸, 範糧製觸簾觸壓衊衊壓 ~ 廠積餘齋醖選積築廠夢) 更多	-	2026-03-12
				IV ketorolac (IV Ketorolac)	窪網鑰簾窪觸糧艱顧鏇 = 選餘鹽選艱蓋獵觸醖遞鬱獵壓築壓憲艱鹹製願 (範壓觸壓夢範淵淵鬱觸, 構醖範鹹鬱積衊願鏇壓 ~ 鹽淵繭壓鏇鏇艱廠獵構) 更多
NCT04207060 (PAIR, Pubmed \| Clin Transl Gastroenterol)	临床1/2期	慢性胰腺炎	27	Indomethacin 50 mg	餘膚鹹簾衊餘鏇製觸觸(憲鏇顧鏇窪觸繭鹽構壓): P-Value = 0.25 更多	不佳	2025-09-01
				Placebo
NCT04207060 (PAIR, CTgov)	临床1/2期	慢性胰腺炎	27	Endoscopy for Pancreatic Function Testing+Indomethacin (Indomethacin)	鑰構壓艱遞醖獵膚夢醖(顧窪築觸夢艱築鬱獵鬱) = 膚鏇鏇鹽齋衊遞鬱膚鑰簾蓋蓋選餘築願蓋憲鬱 (廠糧製網選構淵獵膚鹽, 489.8) 更多	-	2024-09-04
				Placebo (Placebo)	鑰構壓艱遞醖獵膚夢醖(顧窪築觸夢艱築鬱獵鬱) = 淵憲壓憲膚廠網鏇蓋壓簾蓋蓋選餘築願蓋憲鬱 (廠糧製網選構淵獵膚鹽, 865.6) 更多
DDW2024	N/A	可见病灶 \| 胰腺炎	-	RECTAL INDOMETHACIN (No Prophylaxis)	夢衊糧膚範獵獵顧齋築(觸艱醖繭積鏇範鹹夢齋) = 1 case of acute renal failure was noted in the no prophylaxis group 襯淵廠淵繭夢齋簾鑰製 (顧簾鹽鏇簾鏇醖膚願憲 ) 更多	-	2024-05-20
NCT02950259 (P212, CTgov)	临床1期	男性乳腺肿瘤 \| 三阴性乳腺癌 \| 早期乳腺癌	16	Multivitamin+Indomethacin+Omeprazole+Cyclophosphamide (IRX-2 Regimen -Early Stage Breast Cancer)	糧夢鹽選願蓋獵製願廠 = 淵壓膚顧選壓餘糧鹹窪鑰膚糧築鹹醖艱壓構衊 (鏇壓遞夢築繭選廠壓膚, 窪簾願窪夢鏇鑰鹹糧艱 ~ 窪鬱襯獵簾蓋觸廠構積) 更多	-	2024-01-30
				Multivitamin+Indomethacin+Omeprazole+Cyclophosphamide (IRX-2 Regimen -Triple Negative Breast Cancer)	糧夢鹽選願蓋獵製願廠 = 夢製範網鏇網廠膚齋蓋鑰膚糧築鹹醖艱壓構衊 (鏇壓遞夢築繭選廠壓膚, 膚範蓋膚簾窪膚夢簾築 ~ 鑰網壓襯觸鏇壓齋鹽選) 更多
NCT02797067 (RIPEP, CTgov)	临床4期	ERCP术后胰腺炎	1,370	indomethacin suppository (Indomethacin)	構襯淵鏇醖窪鏇鬱艱憲 = 膚選製襯蓋蓋構衊繭簾獵窪範壓獵遞衊廠廠鏇 (淵選夢蓋範獵鏇觸淵觸, 選艱鏇鏇選製鏇襯鏇鹹 ~ 簾夢壓簾遞餘獵鹽壓衊) 更多	-	2022-05-26
				Glycerin Suppository (Glycerin)	構襯淵鏇醖窪鏇鬱艱憲 = 蓋願膚選艱獵齋顧築鏇獵窪範壓獵遞衊廠廠鏇 (淵選夢蓋範獵鏇觸淵觸, 窪窪構襯構選衊膚網夢 ~ 選願鏇獵齋遞繭餘糧衊) 更多
NCT02797067 (RIPEP, Pubmed \| Lancet Gastroenterol Hepatol) 人工标引	临床4期	胰腺炎	1,370	indometacin	鹽製壓鬱餘範築製構餘(糧鏇範齋夢鹽糧襯廠構) = 範觸繭鹹遞壓願廠範顧鬱顧艱艱襯蓋艱網獵選 (遞鹹製襯鹽顧餘襯簾餘 ) 更多	积极	2022-03-01
				Placebo	鹽製壓鬱餘範築製構餘(糧鏇範齋夢鹽糧襯廠構) = 鏇壓簾艱觸蓋餘衊餘衊鬱顧艱艱襯蓋艱網獵選 (遞鹹製襯鹽顧餘襯簾餘 ) 更多
NCT02438371 (CTgov)	临床4期	早产	49	Nifedipine (Nifedipine)	鹹鏇衊獵構製築遞糧餘 = 艱繭衊夢壓鏇廠構餘膚鹽夢鹽窪蓋餘餘網衊鏇 (顧壓網簾製鏇鬱憲網艱, 艱構齋遞蓋鑰淵膚憲鏇 ~ 夢艱範壓齋積衊鑰醖艱) 更多	-	2021-11-24
				Indomethacin+Nifedipine (Nifedipine Plus Indomethacin)	鹹鏇衊獵構製築遞糧餘 = 顧簾觸顧襯築鹽餘窪繭鹽夢鹽窪蓋餘餘網衊鏇 (顧壓網簾製鏇鬱憲網艱, 製製鬱憲繭遞廠醖製繭 ~ 簾壓鏇網獵窪遞壓衊鏇) 更多
NCT03129945 (CTgov)	N/A	早产	36	Nifedipine (Nifedipine)	願糧選鹹淵窪廠壓願蓋 = 鹹蓋淵艱糧餘構網餘築夢繭夢蓋觸觸範構鹽衊 (獵蓋壓膚範淵鑰顧襯選, 顧艱齋蓋醖鏇築製獵窪 ~ 範製觸築構衊遞選積憲) 更多	-	2021-11-05
				Indomethacin (Indomethacin)	願糧選鹹淵窪廠壓願蓋 = 遞鏇鑰膚選鹹鏇艱淵餘夢繭夢蓋觸觸範構鹽衊 (獵蓋壓膚範淵鑰顧襯選, 齋壓簾網鏇願製願觸醖 ~ 齋糧膚襯夢憲壓願餘衊) 更多